Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.09 (0.88%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $10.45 +0.12 (1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/05/2025
Time: AMC |
6/2025 | $-0.24 | 0.00% |
Earnings Summary
For their last quarter, Adaptive Biotechnologies (ADPT) reported earnings of -$0.20 per share, beating the Zacks Consensus Estimate of $-0.28 per share. This reflects a positive earnings surprise of 28.57%. Look out for ADPT's next earnings release on August 05, 2025. For the next earning release, we expect the company to report earnings of -$0.24 per share, reflecting a year-over-year increase of 7.69%.
Earnings History
Price & Consensus
Zacks News for ADPT
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
ADPT FAQs
Adaptive Biotechnologies Corporation (ADPT) has announced they will report their next quarter earnings on August 05, 2025. For the next earning release, we expect the company to report earnings of $-0.24 per share, reflecting a year-over-year increase of 7.69%.
Adaptive Biotechnologies Corporation has announced they will report their previous quarter earnings after the close of the market on August 05, 2025.
The Zacks Consensus Estimate for Adaptive Biotechnologies Corporation (ADPT) for the quarter ending June 2025 is $-0.24 a share. We expect Adaptive Biotechnologies Corporation (ADPT) to report earnings in line with the consensus estimate of $-0.24 per share
In the earnings report for the quarter ending in June 2024, Adaptive Biotechnologies Corporation (ADPT) announced earnings of $-0.26 per share versus the Zacks Consensus Estimate of $-0.32 per share, representing a surprise of -18.75%.